[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100379332":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":41,"responsibleParty":67,"collaborators":26,"id":71,"slug":72,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":73,"sex":79,"minAge":80,"maxAge":26,"enrollmentInfo":81,"targetDuration":26,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":26,"overallStatus":44,"whyStopped":26,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"University Hospital Heidelberg","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Proton Treatment","ACTIVE_COMPARATOR","Patient receive 39 Gy (in 13 fractions (SD 3,0 Gy) Proton Treatment",[13],"Radiation: Proton radiation",{"label":15,"type":16,"description":17,"interventionNames":18},"Carbon Ion Treatment","EXPERIMENTAL","Patient receive 39 Gy (in 13 fractions (SD 3,0 Gy) Carbon Ion Treatment",[19],"Radiation: Carbon Ion radiation",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"RADIATION","Proton radiation","Therapeutic radiation Treatment with Protons",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Carbon Ion radiation","Therapeutic radiation Treatment with Carbon Ions",[15],[32,38],{"name":33,"role":34,"phone":35,"phoneExt":36,"email":37},"Juergen Debus, Prof.","CONTACT","+496221","8201","juergen.debus@med.uni-heidelberg.de",{"name":39,"role":34,"phone":35,"phoneExt":36,"email":40},"Katharina Kozyra, Dr","katharina.kozyra@med.uni-heidelberg.de",[42],{"facility":43,"status":44,"city":45,"state":26,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"University Hospital of Heidelberg, Radiation Oncology","RECRUITING","Heidelberg","69120","Germany","DE",{"type":50,"coordinates":51},"Point",[52,53],8.69079,49.40768,{"lat":53,"lon":52},[56,61,64],{"name":57,"role":34,"phone":58,"phoneExt":59,"email":60},"Matthias Uhl, PD","+49-6221-56","8202","Matthias.uhl@med.uni-heidelberg.de",{"name":62,"role":34,"phone":58,"phoneExt":59,"email":63},"Adriane Hommertgen","adriane.hommertgen@med.uni-heidelberg.de",{"name":65,"role":66,"phone":26,"phoneExt":26,"email":26},"Katharina Seidensaal, MD","SUB_INVESTIGATOR",{"type":68,"investigatorFullName":69,"investigatorTitle":70,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Juergen Debus","Princip Investigator","100379332","neoadjuvant-irradiation-of-retroperitoneal-soft-tissue-sarcoma-with-ions-retro-ion-100379332",false,"NCT04219202","Neoadjuvant Irradiation of Retroperitoneal Soft Tissue Sarcoma With Ions Retro-Ion","Neoadjuvant Irradiation of Retroperitoneal Soft Tissue Sarcoma With Ions Retro-Ion Prospektive Randomisierte Phase-II-Studie","Retro-Ion","Inclusion Criteria:\n\n* Histologically confirmed retroperitoneal soft-tissue sarcoma which is resectable or marginally resectable\n* Karnofsky index of ≥ 70%\n* Age from 18 years\n* Completed patient information and written consent\n* ability to give consent\n\nExclusion Criteria:\n\n* Stage IV (distant metastases)\n* Lymphogenic metastasis\n* Metal implants at the level of the sarcoma, which influence the treatment planning\n* Previous radiation therapy in the treatment area\n* Desmoid tumors, peritoneal sarcomatosis, GIST\n* Simultaneous participation in another clinical study that could influence the results of the respective study\n* Active medical implants for which there is no license for ion irradiation at the time of treatment (e.g. pacemaker, defibrillator)\n* Pregnant women","ALL","18 Years",{"count":82,"type":83},64,"ESTIMATED","INTERVENTIONAL",[86],"NA","The study is a randomized, open, prospective phase II study. The aim of the study is to evaluate the safety and feasibility of a hypofractionated, accelerated radiation approach based on the incidence of grade 3-5 NCI Common Terminology Criteria for Adverse Events (NCI-CTC-AE ) toxicity and \u002F or termination of the planned therapy for any reason with neoadjuvant radiation with active beam guidance of the retroperitoneal Sarcomas using protons or carbon ions before a subsequent tumor resection.",[89],"Sarcoma,Soft Tissue","2026-03-06",{"date":92,"type":93},"2026-03-10","ACTUAL",{"date":95,"type":93},"2019-05-09",{"date":97,"type":83},"2027-05-09",{"name":5,"class":6},1]